number of access : ?
number of downloads : ?
ID 115865
Author
Keywords
sodium-glucose co-transporter-2 inhibitors (SGLT2i)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection trial (DAPA-HF) Empagliflozin outcome trial in Patients with chronic heart Failure with Reduced Ejection Fraction trial (EMPEROR-Reduced)
dapagliflozin-chronic kidney disease trial (DAPA-CKD)
the evaluation of Ertugliflozin efficacy and Safety Cardiovascular outcomes trial (VERTIS-CV)
Content Type
Journal Article
Description
Recently, sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been a topic for oral hypoglycemic agents (OHAs) for diabetes. It suggested positive effects on the heart and kidneys from EMPAREG-OUTCOME study, CANVAS program, and DECLARE-TIMI 58 study. SGLT2i are expected to become the useful agents that transcend OHAs, from three recent reports. They are i) Dapagliflozin in Patients with Heart Failure and Reduced Ejection trial (DAPA-HF), ii) the Empagliflozin outcome trial in Patients with chronic heart Failure with Reduced Ejection Fraction trial (EMPEROR-Reduced), and iii) dapagliflozin-chronic kidney disease trial (DAPA-CKD). SGLT2i may become an agent for late-aging and longevity in the future.
Journal Title
Recent Research in Endocrinology and Metabolic Disorder
ISSN
27175138
Volume
3
Issue
1
Start Page
27
End Page
30
Published Date
2021-03-27
Rights
This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences